Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Future studies should prioritize early PsA populations, ideally using stratified designs that incorporate metabolic profiling, to fully elucidate the dual immunomodulatory and metabolic potential of GLP-1RAs in altering disease trajectory
Zhang H, Ni W, Yu G, et al
The dimeric copper peptide D-CuP showed superior antioxidant properties compared to M-CuP, leading to a notable decrease in relative fluorescence intensity
In the present in vitro study, we confirmed that the levels of p-Akt were increased by L-carnitine in a time-dependent manner in the myotubes with TNF--induced atrophy (Fig
The Obesity Action Coalition provides free appeal letter templates and advocacy resources
Abstract Aims Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity
US$ 25.28
US$ 20.65
US$ 21.11
US$ 26.45
US$ 27.79
US$ 27.19
US$ 29.10
US$ 29.39
US$ 22.17
US$ 20.88
US$ 26.77
US$ 23.45
